A phase Ib/II study of the anti-CD47 antibody magrolimab with cetuximab in solid tumor and colorectal cancer patients.
George A. Fisher(Stanford University), Amita Patnaik(South Texas Accelerated Research Therapeutics), Jens-Peter Volkmer(Menlo School), Benny Johnson(The University of Texas MD Anderson Cancer Center), Roy L. Maute(Io Therapeutics (United States)), Yan V. Wang(Menlo School), Adel Kardosh(Stanford University), Johanna C. Bendell(Dana-Farber Cancer Institute), Peter J. O’Dwyer(University of Pennsylvania), Balaji Agoram(Menlo School), Chris H. Takimoto(Menlo School), Philip Agop Philip(Wayne State University), Tina M Ippolito(Menlo School), Isagani Chico, Mark P. Chao(Stanford Medicine), Nehal J. Lakhani(South Texas Accelerated Research Therapeutics), J. Randolph Hecht(Ontario Institute for Cancer Research), Cathy Eng(Vanderbilt University)
Cited by 53
Related Papers
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k